Evaluation of subcutaneous versus mucosal (intranasal) allergen-specific rush immunotherapy in experimental feline asthma

Veterinary Immunology and Immunopathology

Volumn 129, Issue 1-2, 2009, Pages 49-56

  Lee Fowler, Tekla M ^a   Cohn, Leah A ^a   DeClue, Amy E ^a   Spinka, Christine M ^b   Reinero, Carol R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Airway inflammation; Animal model; Hyposensitization; Mucosal immunotherapy; Tolerance

Indexed keywords

ALLERGEN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BERMUDA; CYTOKINE PRODUCTION; EOSINOPHIL; EVALUATION; FELINE ASTHMA; FEMALE; IMMUNOTHERAPY; LUNG LAVAGE; MALE; NONHUMAN; RESPIRATORY TRACT DISEASE; RUSH IMMUNOTHERAPY; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ALLERGENS; ANIMALS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CAT DISEASES; CATS; CELL COUNT; CYNODON; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILS; FEMALE; INJECTIONS, SUBCUTANEOUS; MALE; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS;

ANIMALIA; CYNODON DACTYLON; FELIDAE;

EID: 62549144808     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.12.008     Document Type: Article

References (31)

1. Allam J.P., Niederhagen B., Bucheler M., Appel T., Betten H., Bieber T., Berge S., and Novak N. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 61 (2006) 166-172
2. Allam J.P., Novak N., Fuchs C., Asen S., Berge S., Appel T., Geiger E., Kochan J.P., and Bieber T. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol. 112 (2003) 141-148
3. Allam J.P., Peng W.M., Appel T., Wenghoefer M., Niederhagen B., Bieber T., Berge S., and Novak N. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121 (2008) 368-374 e361
4. Bousquet J., Demoly P., and Michel F.B. Specific immunotherapy in rhinitis and asthma. Ann. Allergy Asthma Immunol. 87 (2001) 38-42
5. Bousquet J., Jeffery P.K., Busse W.W., Johnson M., and Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodelling. Am. J. Respir. Crit. Care Med. 161 (2000) 1720-1745
6. Boyaka P., Tafora A., Fischer R., Fujihashi K., Jirillo E., and McGhee J. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr. Pharm. Des. 9 (2003) 1965-1972
7. Cohn L., Elias J., and Chupp G. Asthma: mechanisms of disease persistence and progression. Ann. Rev. Immunol. 22 (2004) 789-815
8. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann. Allergy Asthma Immunol. 97 (2006) 126-137 quiz 137-140, 202
9. Czerkinsky C., Anjuere F., McGhee J., George-Chandy A., Holmgren J., Kieny M., Fujiashi K., Mestecky J., Pierrefite-Carle V., Rask C., and Sun J. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170 (1999) 197-222
10. Fixman E.D., Stewart A., and Martin J.G. Basic mechanisms of development of airway structural changes in asthma. Eur. Respir. J. 29 (2007) 379-389
11. Griffin C.E., and Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet. Immunol. Immunopathol. 81 (2001) 363-383
12. Hawkins E.C., DeNicola D.B., and Kuehn N.F. Bronchoalveolar lavage in the evaluation of pulmonary disease in the dog and cat. State of the art. J. Vet. Intern. Med. 4 (1990) 267-274
13. Horner A., Ronaghy A., Cheng P.-M., Nguyen M., Cho H., Broide D., and Raz E. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190 (1998) 77-82
14. Janeway C., Travers P., Walport M., and Shlomchik M. Immunobiology: The Immune System in Health and Disease. 5th Edition (2001), Garland Publishing, New York
15. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., and Malling H.J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
16. Kohno Y., Minoguchi K., Oda N., Yokoe T., Yamashita N., Sakane T., and Adachi M. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J. Allergy Clin. Immunol. 102 (1998) 927-934
17. Lima M.T., Wilson D., Pitkin L., Roberts A., Nouri-Aria K., Jacobson M., Walker S., and Durham S. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin. Exp. Allergy 32 (2002) 507-514
18. Lockey R.F., Nicoara-Kasti G.L., Theodoropoulos D.S., and Bukantz S.C. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 87 (2001) 47-55
19. Marogna M., Spadolini I., Massolo A., Canonica G.W., and Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 59 (2004) 1205-1210
20. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., and Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 (2006) 151-165
21. Pajno G.B., Vita D., Parmiani S., Caminiti L., La Grutta S., and Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin. Exp. Allergy 33 (2003) 1641-1647
22. Passalacqua G., and Canonica G. Allergen-specific sublingual immunotherapy for respiratory allergy. BioDrugs 15 (2001) 509-519
23. Reinero C.R., Byerly J.R., Berghaus R.D., Berghaus L.J., Schelegle E.S., Hyde D.M., and Gershwin L.J. Rush immunotherapy in an experimental model of feline allergic asthma. Vet. Immunol. Immunopathol. 110 (2006) 141-153
24. Reinero C.R., Cohn L.A., Delgado C., Spinka C.M., Schooley E.K., and Declue A.E. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet. Immunol. Immunopathol. 121 (2008) 241-250
25. Rossi R., and Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int. J. Immunopathol. Pharmacol. 18 (2005) 277-285
26. Rossi R.E., and Monasterolo G. Safety of ultra-rush (two hours) sublingual-swallow immunotherapy in allergic patients. Giorn. It. Allergol. Immunol. Clin. 12 (2002) 221-226
27. Scott D.W., Miller Jr. W.H., and Griffin C.E. Muller and Kirk's Small Animal Dermatology. 6th Edition (2001), Saunders, St. Louis, MO pp. 597-601
28. Takabayashi K., Libet L., Chisholm D., Zubeldia J., and Horner A. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J. Immunol. 170 (2003) 3898-3905
29. Till S.J., Francis J.N., Nouri-Aria K., and Durham S.R. Mechanisms of immunotherapy. J. Allergy Clin. Immunol. 113 (2004) 1025-1034 quiz 1035
30. Wiedermann U., Herz U., Vrtala S., Neuhaus-Steinmetz U., Renz H., Ebner C., Valenta R., and Kraft D. Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma. Int. Arch. Allergy Immunol. 124 (2001) 391-394
31. Wilson D.R., Lima M.T., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 (2005) 4-12